Skip to main content
OpenTrials
Completed

NCT Number: NCT02187705

Micardis® in Patients With Essential Hypertension

The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with essential hypertension
  • Minimum age of 18 years

Exclusion criteria

Not applicable

Treatment and study plan

Telmisartan tablets

Drug

All patients were treated with different doses of telmisartan for 14 days

Other names: Micardis®

Primary outcomes

  1. Changes from baseline in blood pressure

    Time frame: Up to 14 days

    Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)

  2. Number of patients with adverse events

    Time frame: Up to 14 days

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

Important dates

Study start
1999
Primary completion
2000
First posted
Jul 11, 2014
Registry last updated
Jul 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.